Abstract
BackgroundThe approval of mutant-specific KRASG12C inhibitors (G12Ci) has changed the clinical practice for lung cancer patients harbouring KRASG12C mutations. However, responses to G12Ci are short-lived as a result of rapid...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
